Accepted papers with an effective registration will be published in Proceedings.
Results that have been presented at meetings of other scientific societies are eligible for presentation, provided they have not been published (except in abstract form) either on-line ahead of print, or in printed version before December 31st, 2020.
The author must submit at the Participant's Area an abstract with a single paragraph of 250 to 300 words, in English. It must contain: context, objectives, method, results and conclusion, according to the instructions below:
Background: One or two sentences that describe the clinical (or other) importance of the study question.
Objectives: The main objective(s) or study question stated in infinitive form (e. g. “To determine…”). If study were to test an a priori hypothesis, it should be stated.
Methods: Should include statements that address:
1. Design: Basic study design, source population, follow-up; dataset (for new analyses of existing data); statement of criterion standard and any blinding (studies of screening or diagnostic test); matching and selection of controls, if relevant; analysis type (e.g., cost-effectiveness, cost-benefit, etc.) if an economic analysis.
2. Setting: Eligibility, inclusion/exclusion criteria, and for surveys and follow-up studies, the number eligible versus the number/proportion remaining in the analysis.
3. Exposures or interventions: explicit naming of medications or other interventions. Nonproprietary names should be used.
4. Main outcome measures: the primary and secondary outcome measurement(s) as determined prior to data collection. If hypothesis was formulated after data collection, this should be stated.
5. Statistical analysis: The statistical methods should be described.
Results: Provide and quantify the main outcomes of the, including confidence intervals and/or other significance tests. If differences are not significant, state the clinically important difference sought and give the confidence interval for the difference between the groups. For studies reporting risk changes or effect sizes, provide absolute values to make it possible to the reader determine the absolute as well as relative impact of the result. Report sensitivity, specificity, and likelihood ratio to screening and diagnostic test studies and if predictive value or accuracy is given, prevalence or pretest likelihood should be provided.
Conclusions: Describe the conclusions that are directly supported by the reported data, along with their implications (avoid speculation and overstatement of findings). Emphasis should be given equally to positive and negative findings of equal scientific merit.
Research abstracts consistent with the following categories will be accepted:
AUTHORS, COAUTORS AND INSTITUTIONAL BOND
- Drug Utilization Research/ Promotion of Rational Use of Medicine
- Health Technology Assessment
- Methods in Clinical Epidemiology
- Economic Research and Equity
- Global Health System and Environment
- Innovation and development of health technologies
Insert the full name of the author and co-authors, respecting one name per line.
The oral presentation of the posters will take place online (live) through the event's website. The day and time of the presentation will be posted on the event page. The oral presentation of the poster will last for 3 minutes, followed by another 3 minutes of discussion.
ABSTRACT SELECTION AND PRESENTATION
All abstracts will be submitted to a peer review process. A communication of acceptance or non-acceptance will be sent at the end of this process.
Thereafter, a second communication with specific session details of the presentation will be sent to the presenters by February 22nd, 2021
If an abstract is accepted for presentation, an author or person designated by the author must attend the session to present the poster to be published in the congress program. Only one poster will be accepted per first registered author, responsible for the content of the poster. Each abstract will need a unique record.
Poster presenters must prepare a poster and an oral presentation. Posters must be in English. Oral presentations can be prepared either in English, Portuguese or Spanish.
the file must be attached in PDF format, with a maximum size of 2MB.
The best posters will be awarded after oral presentation in small groups.
Once published, the files will not be able to undergo any further changes or corrections.
The proceedings will be published in the Brazilian Journal of Pharmaceutical Science, QUALIS CAPES - B1.